AME entered an official partnership with Publons to enhance wide-ranging recognition for reviewers

AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as of April 2020. Around 60 AME journals’ peer review systems are now integrated seamlessly into the Publons platform (https://publons.com/about/home). The partnership was done to recognize our expert peer reviewers spontaneously for their review contribution.

Read More>>

The surprising importance of gut microbiota in tackling flu infection

Our understanding of defence mechanisms raised against a given pathogen (e.g., influenza virus infection) is mainly focused on innate and adaptive immune cells responses, but other cell types such as stromal cells most certainly constitute an important first line of defence against invading pathogens.

Read More>>

The emerging role of trogocytosis in the evasion of cancers and parasitic protists from immune cells

To improve CAR T cell therapy, one potential approach will be regulating trogocytosis of CAR T cells. To this end, understand the molecular mechanisms is indispensable. Unfortunately, molecular basis of trogocytosis is not well clarified except for trogocytosis specific AGC family kinase in E. histolytica, most of the report showing molecules shared with phagocytosis. Studies of molecular basis of trogocytosis in model organisms and protists will provide novel drug target.

Read More>>

Implementation of transparent peer review at Biotarget

With a commitment to openness and accountability, and to increase the level of transparency throughout our peer review process, our editorial office has decided to implement a transparent peer review process as an option for all manuscripts submitted to Biotarget from March 19, 2020.

Read More>>

Application of the CARE Guideline as reporting standard in Biotarget

Biotarget welcomes case reports which are supposed to report newobservations of diseases, clinical findings or novel/unique treatment outcomesrelevant to practitioners in the fields of medicine.

For completeness andtransparency for published case reports, Biotarget will apply the CARE guidelines(1) as reporting standards for case reports starting from October 14, 2019. Forany submission of case report after the date:

Read More>>

Biotarget: a platform to rapidly disseminate knowledge and exchange experiences in biotarget molecules

It is my pleasure and great privilege to present the starting issue of Biotarget to you. This is a new international peer-reviewed journal devoted to the rapid publication of high-quality studies related to identifying key biotarget molecules and the application of biotarget molecules in human and animal disease, available in print and online.

Read More>>

Editor-in-Chief: Maorong Jiang, MD

Dr. Maorong Jiang received his doctorate in Human Anatomy and Embryology form Soochow University in 2012. He worked in Jiangsu Key Laboratory of Neuroregeneration (Co-innovation Center of Neuroregeneration) in Nantong University from 2003-2014, and mainly engaged in peripheral nerve regeneration. In 2014, he is currently a vice Professor and vice Director of Laboratory Animal Center of Nantong University, and mainly engaged in animal model of human disease and transgenic animal. Dr. Jiang achieved the National Natural Science Foundation of China and the Natural Science Foundation of Jiangsu Province.

Read More>>